- Home
- AIRT vs CUE Comparison
AIRT vs CUE Comparison
Compare AIRT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- CUE
- Stock Information
- Founded
- AIRT 1980
- CUE 2014
- Country
- AIRT United States
- CUE United States
- Employees
- AIRT N/A
- CUE N/A
- Industry
- AIRT Air Freight/Delivery Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- CUE Health Care
- Exchange
- AIRT Nasdaq
- CUE Nasdaq
- Market Cap
- AIRT 61.2M
- CUE 61.1M
- IPO Year
- AIRT N/A
- CUE 2018
- Fundamental
- Price
- AIRT $18.35
- CUE $0.56
- Analyst Decision
- AIRT
- CUE Strong Buy
- Analyst Count
- AIRT 0
- CUE 2
- Target Price
- AIRT N/A
- CUE $3.00
- AVG Volume (30 Days)
- AIRT 1.4K
- CUE 394.8K
- Earning Date
- AIRT 11-12-2025
- CUE 11-12-2025
- Dividend Yield
- AIRT N/A
- CUE N/A
- EPS Growth
- AIRT N/A
- CUE N/A
- EPS
- AIRT N/A
- CUE N/A
- Revenue
- AIRT $279,216,000.00
- CUE $7,100,000.00
- Revenue This Year
- AIRT N/A
- CUE N/A
- Revenue Next Year
- AIRT N/A
- CUE N/A
- P/E Ratio
- AIRT N/A
- CUE N/A
- Revenue Growth
- AIRT N/A
- CUE N/A
- 52 Week Low
- AIRT $14.56
- CUE $0.54
- 52 Week High
- AIRT $26.70
- CUE $1.75
- Technical
- Relative Strength Index (RSI)
- AIRT 26.31
- CUE 28.56
- Support Level
- AIRT $20.93
- CUE $0.57
- Resistance Level
- AIRT $21.00
- CUE $0.62
- Average True Range (ATR)
- AIRT 0.34
- CUE 0.08
- MACD
- AIRT -0.36
- CUE -0.01
- Stochastic Oscillator
- AIRT 0.00
- CUE 0.53
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.